ACHV Achieve Life Sciences Inc
Company Analysis
Latest News
venBio Partners Takes 5.75% Stake in Achieve Life Sciences, Eyeing 2027 Launch
venBio Partners LLC acquired 5,914,720 shares of Achieve Life Sciences. This investment represents a 5.75% stake in the biopharmaceutical company. The position...
🟢 Achieve Life Sciences rises 5.5% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
🟢 Achieve Life Sciences is trading 5.5% up in pre-market without a clear company-specific catalyst
Achieve Life Sciences is trading 5.51% up now at $8.38 after no clearly reported company-specific catalyst emerged for August 25, 2026. - Latest material...
🟢 Achieve Life Sciences is trading 6% up in pre-market today amid a possible biotech sentiment rebound
Achieve Life Sciences is trading at $8.50 (+5.99%), with no new company-specific announcement dated August 21, 2026 identified. - The latest official listing...
🔴 Achieve Life Sciences falls 5.2% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
Achieve Life Sciences Hits 52-Week High, Advancing Smoking Cessation Drug
Achieve Life Sciences (NASDAQ:ACHV) reached a new 52-week high of $7.60 on Wednesday. The stock closed the session at $7.52. Investor confidence is growing in...
🟢 Achieve Life Sciences is trading 10.2% up today amid biotech-sector momentum
Achieve Life Sciences is trading 10.2% up at $8.29, with sector momentum the clearest explanation on August 19, 2026. - The stock is outperforming the broader...
🟢 Achieve Life Sciences rises 6.4% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
Achieve Life Sciences launches $150 million at-the-market program for cytisinicline during third quarter 2026
Achieve Life Sciences entered into an at-the-market (ATM) equity offering agreement to sell up to $150.0 million in common stock. The company intends to...
🟢 Achieve Life Sciences is trading 5.68% up today after Morgan Stanley initiated Overweight coverage
Achieve Life Sciences is trading at $7.07 (+5.68%) after Morgan Stanley initiated coverage on August 13, 2026, with an Overweight rating and a $13.00 price...
Achieve Life Sciences second quarter cash hits $187M as fourth quarter NDA resubmission nears
Achieve Life Sciences reported a net loss of $74.8 million for the second quarter of 2026, a result heavily impacted by a $48.7 million non-cash warrant...
Achieve Life Sciences Reports Q2 Results, Shifts Manufacturing to United States
Achieve Life Sciences announced its second-quarter 2026 financial results on August 10, 2026. The clinical-stage pharmaceutical company is currently advancing...
🟢 Achieve Life Sciences is trading 5% up today in pre-market
Achieve Life Sciences is trading 5% up now at $6.88 in pre-market after rising from the August 6 close of $6.55; no clear catalyst was identified. - No clear...
🔴 Achieve Life Sciences is trading 5.9% down today ahead of its August 6 earnings report
Achieve Life Sciences is trading 5.9% down at $6.09 as investors appear to be repositioning ahead of the company's upcoming quarterly financial results. • The...
Achieve Life Sciences Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Achieve Life Sciences is projected to report a consensus EPS loss of $0.18 on zero revenue for Q2 2026, with the stock currently trading at $4.42 against an...
🔴 Achieve Life Sciences is trading 7.3% down today amid low-liquidity pre-market dynamics
Achieve Life Sciences is trading at $5.95 (7.3% down), reversing its mild gains from late July. • The move appears driven by typical low-liquidity pre-market...
🟢 Achieve Life Sciences is trading 5.4% up today on continued momentum and market sentiment
Achieve Life Sciences is trading at $6.43 (+5.41%) today, extending recent gains amid a broader risk-on market sentiment. • The stock continues to build on...
🟢 Achieve Life Sciences is trading 5.4% up today in a rebound following a selloff driven by an FDA Complete Response Letter
Achieve Life Sciences is trading 5.4% up today at $6.28, rebounding after a sharp decline triggered by an FDA Complete Response Letter (CRL) for cytisinicline...
🔴 Achieve Life Sciences is trading 5.3% down today following FDA CRL and financing pressure
Achieve Life Sciences is trading 5.3% down at $6.00, extending a decline triggered by an FDA Complete Response Letter (CRL) for cytisinicline and significant...
🔴 Achieve Life Sciences Is Trading 6.7% Down Today Amid Annual Stockholder Meeting and Share Increase Proposal
Achieve Life Sciences is trading 6.7% down at $5.97 today, following its 2026 Annual Meeting of Stockholders. During the meeting, stockholders voted on a...